[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ureter-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ureter-cancer":50},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,100,133,162,188,216,239],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":77,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100210159","integrated-cancer-repository-for-cancer-research-100210159",false,"NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals",true,"ALL","19 Years","110 Years",{"count":21,"type":22},999999,"ESTIMATED","80 Years","OBSERVATIONAL","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76],"Pancreatic Cancer","Thyroid Cancer","Lung Cancer","Esophageal Cancer","Thymus Cancer","Colon Cancer","Rectal Cancer","Gastrointestinal Stromal Tumors","Anal Cancer","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Gastric Cancer","Liver Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Bladder Cancer","Kidney Cancer","Penile Cancer","Prostate Cancer","Testicular Cancer","Ureter Cancer","Urethral Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Salivary Gland Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Breast Cancer","Leukemia","Melanoma","Sarcoma","Unknown Primary Tumor","Multiple Myeloma","Ovarian Cancer","Endometrial Cancer","Vaginal Cancer","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[27,28,78,79,80,81,82,83,84,85,65,86,75,76],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","RECRUITING","2026-06-25",{"date":90,"type":91},"2026-06-29","ACTUAL",{"date":93,"type":91},"2013-11-01",{"date":95,"type":22},"2099-12",{"name":97,"class":98},"University of Nebraska","OTHER",42,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100542961","phase-3-spinal-morphine-or-intravenous-lidocaine-in-robot-assisted-upper-urologic-surgery-100542961","NCT06349668","Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery","SMILe: Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery","SMILe","Inclusion Criteria:\n\n* The patient is scheduled for elective robotic-assisted upper urinary tract surgery at one of the participating hospitals\n* The patient gives oral and written informed consent after having received oral and writen information about the study\n\nExclusion Criteria:\n\n* The patient has a ASA-class of IV or above\n* The patient is a minor or declared incompetent, has severe psychiatric disease or is expected not to be able to understand the study information due to severe restrictions in vision, hearing, cognition, reading or Swedish language abilities\n* The patient is a female who is pregnant or breastfeeding\n* The patient is a pre-menopausal female who has not undergone sterilisation, hysterectomy, bilateral salpingectomy and\u002For bilateral oophorectomy, and is not using highly-effective contraception with low user-dependency and cannot provide a negative pregnancy test\n* The patient is scheduled for emergency surgery\n* Research staff not available\n* Scheduled significant simultaneous surgery on another organ\n* The anesthesiologist in charge has planned spinal or epidural analgesia\n* The patient has clear contraindications to spinal analgesia, e.g. severe coagulopathy, severe aortic stenosis, previous back surgery with rods, or spinal analgesia can be expected to be technically challenging (severe obesity, severe scoliosis)\n* The patient has clear contraindications to lidocaine infusion, e.g. proven allergy to local anesthetics, myasthenia gravis, renail failure (eGFR \\\u003C 30), hepatic failure caused by acute hepatitis or cirrhosis (Child-Pugh B or higher, severe cardiac arrythmias or insuffiency (NYHA IIIb or higher)\n* The patient has previously participated in the trial","18 Years",{"count":110,"type":22},220,"INTERVENTIONAL",[113],"PHASE3","The goal of this clinical trial is to learn whether the addition of spinal analgesia leads to superior recovery in patients undergoing robotic-assisted laparoscopic upper urinary tract surgery under general anesthesia. The main questions it aims to answer are:\n\n* Is the decrease in wellbeing as quantified by the patient-centered outcome scale \"Quality of Recovery 15\" (QoR-15), from baseline to the first day after surgery (POD 1), at least 8.0 points less in patients receiving spinal analgesia in addition to general anesthesia?\n* Does spinal analgesia result in improved recovery as quantified by QoR-15 at POD 7, the incidence of postoperative pain at rest and at mobilization, nausea and vomiting, the need for opioid analgesics, time out-of-bed, length of stay and the incidence of complications?\n* Does spinal analgesia increase workload in the OR, as quantified by time from arrival in the OR to start of surgery?\n* Does spinal analgesia result in an increased incidence of hypotension and cardiac dysfunction during surgery, as well as an increased incidence of pruritus after surgery?\n\nParticipants will be randomized to receive either spinal analgesia with bupivacaine and morphine preoperatively or an intravenous infusion with lidocaine intraoperatively.\n\nQoR-15 and other markers of recovery will be registered using structured interviews preoperatively, at POD1 and POD7. In addition, patients will record pain at rest and at mobilization three times daily in a diary.\n\nIn a subgroup of patients advanced hemodynamic parameters will be recorded using pulse-contour analysis before, during and after surgery. Blood samples will also be collected in these patients at fixed intervals and analyzed for amongst others inflammation and cardiac dysfunction.",[116,117,118,50,119,120,121,122],"Other Specified Disorders of Kidney and Ureter","Benign Neoplasm of Ureter","Calculus of Kidney and Ureter","Ureteric Reflux","Congenital Ureteric Anomaly","Benign Renal Neoplasm","Renal Cancer","2026-02-02",{"date":125,"type":91},"2026-02-05",{"date":127,"type":91},"2024-04-09",{"date":129,"type":22},"2027-12-31",{"name":131,"class":98},"Hans Bahlmann",3,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":23,"enrollmentInfo":140,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100562099","postoperative-adjuvant-immunotherapy-combined-with-radiotherapy-versus-surgery-alone-in-locally-advanced-utuc-100562099","NCT06598761","Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC","Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced Upper Tract Urothelial Carcinoma: a Prospective Observational Cohort Study","Inclusion Criteria:\n\n* 1\\) Patients after radical nephroureterectomy with full-length nephroureterectomy and pathologically confirmed cancer of the renal pelvis or ureter, AJCC staging (8th edition) containing one of the following factors: pT3-4, pN+; 2) Patients with creatinine eGFR \\\u003C60 min\u002FL. or underlying disease refusing to tolerate chemotherapy.\n\n3)18≤age≤80 years old; 4)Completion of abdominopelvic CT 4 weeks prior to enrolment. 5)Except for cutaneous non-melanoma and ductal carcinoma in situ of the breast, the patient has not suffered from any other malignant disease within the last 5 years; 6)Willing to participate in perfecting the necessary examinations and follow-up visits for the sake of the study, and willing to provide written informed consent.\n\nAll of the above need to be fulfilled:\n\nExpected survival \\> 6 months; KPS \\> 70 points; Leukocytes ≥ 3.5 x 109\u002Fl,Neutrophils ≥ 1.5 x 109\u002Fl, Platelets ≥ 100.0 x 109\u002Fl, Haemoglobin ≥ 90g\u002Fl.\n\nExclusion Criteria:\n\n* 1\\) Distant metastases already found at the time of surgery; non-R0 resected patients 2) History of pelvic and abdominal radiotherapy; history of inflammatory bowel disease; history of systemic chemotherapy; (3) Pregnant or breastfeeding women; or women of childbearing potential who are not using reliable contraception; (4) History of malignant tumour (except skin cancer that is not malignant melanoma and cervical cancer in situ, tumours that have been cured for more than 5 years) 5) weight loss \\> 10% within 6 months 6) Presence of active infections in those with pre-existing or co-existing bleeding disorders 7) clinically significant cardiac disease (e.g., hypertension controlled by medication, unstable angina pectoris, New York Heart Association (NYHA) class ≥ II congestive heart failure, unstable symptomatic arrhythmia, or class ≥ II peripheral vascular disease); 8) Psychological, family, and social factors leading to lack of informed consent.",{"count":141,"type":22},60,"This is a prospective cohort study to analyse the safety and efficacy of postoperative adjuvant radiotherapy combined with immunotherapy versus surgery alone group of UTUC patients with T3-4 stages or lymph nodes metastasis(N+) status.",[50,144,145],"Renal Pelvic Carcinoma","Advanced Urothelial Carcinoma",[147,148,149,150,151],"upper tract urothelial carcinoma","Radiotherapy","Immunotherapy","Combined therapy","Prospective cohort study","2024-11-03",{"date":154,"type":91},"2024-11-05",{"date":156,"type":91},"2022-01-01",{"date":158,"type":22},"2027-08-30",{"name":160,"class":98},"Peking University First Hospital",2,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":23,"enrollmentInfo":169,"targetDuration":4,"studyType":111,"phases":171,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":185,"leadSponsor":187,"locationsCount":161},"100566195","radiotherapy-combined-with-systemic-therapy-versus-systemic-therapy-for-oligometastatic-utucs-100566195","NCT06652022","Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs","Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic Upper Tract Urothelial Carcinoma: a Prospective Randomised Controlled Trial","Inclusion Criteria:\n\n* Patients with metastatic uroepithelial cancer with histologically confirmed diagnosis (pathologically confirmed primary focus or one of the metastatic foci is sufficient) (metastasis after total cystectomy, metastasis after full-length nephroureteral resection, or metastatic uroepithelial cancer of the pelvic-ureteral bladder at the first diagnosis of inoperable metastatic uroepithelial cancer).\n* Oligometastases were defined as ≤3 organs, and the number and size of metastatic lesions were not restricted to the extent that full-coverage radiotherapy could be met. If regional lymph node recurrence was present, all positive regional lymph nodes were collectively referred to as one lesion. Non-regional lymph node metastases are counted as metastases by lymph node subregion.\n* Willing and able to provide written informed consent\u002Fassent for the trial; age ≥18 years on the date of signing the informed consent form and patient age ≤80 years.\n* Expected survival time ≥ 6 months;\n* Eastern Collaborative Oncology Group (ECOG) Physical Status (PS) score of 0 to 1;\n* Normal major organ function, i.e., the following criteria are met: routine blood tests: a) Haemoglobin ≥ 90 g\u002FL; b) Total bilirubin ≤ 2 x upper limit of normal (ULN); c) Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) ≤ 2.5 x ULN in the absence of liver metastases, and ALT, AST and ALP ≤ 5 x ULN in the presence of liver metastases; d) Creatinine clearance (CrCl) ≥30 mL\u002Fmin;\n\nExclusion Criteria:\n\n* Pathological type non-urothelial carcinoma;\n* Patients with brain metastases and \\>3 liver metastases; patients with spinal bone metastases at risk of spinal cord compression; patients with pericardial, pleural or abdominopelvic fluid;\n* Patients who are intolerant to or have had a reduction in systemic therapy; patients with tumour progression assessed after 2 cycles of systemic therapy.",{"count":170,"type":22},102,[172],"NA","This study was a prospective, open-label, phase II randomised controlled clinical study, enrolling patients with primary oligometastatic uroepithelial carcinoma, oligometastasis was defined as ≤3 organs, and the number of metastatic lesions and size of metastases were not restricted to be able to satisfy the definition of full-coverage radiotherapy, with the exception of patients with brain metastases and more than 3 liver metastases.\n\nIf regional lymph node recurrence was present, all positive regional lymph nodes were collectively referred to as one lesion. Non-regional lymph node metastases were counted as the number of metastases by lymph node subregion.\n\nPatients were divided into two groups according to whether they received radiotherapy or not: 1) systemic therapy group; 2) systemic therapy + radiotherapy group. Systemic drug therapy can be chosen from chemotherapy or immune checkpoint inhibitor therapy, or combination therapy.",[175,50,144],"Oligometastatic Disease",[175,177,178,179,180],"Upper tract urothelial carcinoma","systematic","radiotherapy","Randomized control trial","2024-10-20",{"date":183,"type":91},"2024-10-22",{"date":156,"type":91},{"date":186,"type":22},"2029-12-30",{"name":160,"class":98},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":198,"conditions":199,"keywords":203,"overallStatus":206,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":213,"locationsCount":215},"100552141","performance-evaluation-of-urine-dna-methylation-testing-for-the-detection-of-urothelial-carcinoma-in-patients-with-hematuria-100552141","NCT06469229","Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria","Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria: a Prospective, Multicenter Cohort Study","Inclusion Criteria:\n\n* Aged between 18 and 99 years, with gross or microscopic hematuria (RBC ≥ 3 \u002FHPF or RBC \\> 18 \u002FμL for men, \\> 33 \u002FμL for women).\n* Able to provide 50ml urine for testing before surgery.\n* Consent to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n* With history of any malignancies (including UC).\n* Severe urinary tract infection leading to sepsis.\n* Patients with indwelling catheters, nephrostomy, or cystostomy.\n* Severe liver or kidney failure or other conditions deemed unsuitable for the study.\n* Patients who did not undergo surgical treatment for various reasons.\n* Samples with insufficient DNA content or other quality control failures.\n* Incomplete clinical or pathological data.\n* Patients currently undergoing intravesical or systemic chemotherapy, radiotherapy, immunotherapy, or targeted therapy.","99 Years",{"count":197,"type":22},1200,"Background Urothelial carcinoma (UC) is the most common malignancy of the urinary system. Hematuria is a significant clinical manifestation of UC, often diagnosed through invasive procedures. Urine DNA methylation testing is a promising non-invasive method for early UC detection.\n\nObjectives To evaluate the sensitivity and specificity of urine DNA methylation testing for detecting UC in patients with hematuria, using standard clinical and pathological diagnoses as the gold standard. This study also aim to investigate the association between preoperative urine DNA methylation status and prognosis in UC patients.\n\nFor non-UC patients: Follow up for one year to assess the risk of UC development based on preoperative urine DNA methylation status.\n\nSample Size Calculation Expected sensitivity: 86% Expected specificity: 90% Significance level (Alpha): 0.05 Total participants needed: 1053 (adjusted for 5% dropout rate, 1109 participants will be recruited).\n\nStudy Procedure Enrollment and Sample Collection: Screen patients, obtain consent, collect urine samples.\n\nBlinding and Testing: Blinded sample processing and DNA methylation testing. Unblinding and Analysis: Statistical analysis of sensitivity and specificity. Reporting: Compilation and consolidation of clinical trial reports.\n\nUrine DNA methylation testing is expected to demonstrate high sensitivity and specificity for diagnosing urothelial carcinoma (UC) in patients with hematuria. This non-invasive diagnostic method promises to deliver valuable information, potentially leading to improved patient outcomes.",[200,201,45,50,202],"Hematuria","Urothelial Carcinoma","Renal Pelvis Cancer",[200,201,204,205],"Urine DNA Methylation","Multicenter","NOT_YET_RECRUITING","2024-07-02",{"date":209,"type":91},"2024-07-05",{"date":211,"type":22},"2024-07-01",{"date":129,"type":22},{"name":214,"class":98},"Changhai Hospital",1,{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":17,"minAge":222,"maxAge":4,"enrollmentInfo":223,"targetDuration":225,"studyType":24,"phases":4,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":215},"100410518","development-of-urologic-registry-for-personalized-medicine-in-patients-with-urologic-malignant-diseases-by-analyzing-microbiome-100410518","NCT04625556","Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome","Inclusion Criteria:\n\n* Patients diagnosed as urological malignancies (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer)\n* Patients who have undergone surgeries due to urological malignancies in Severance Hospital, Sinchon from 2020.10 and 2030.10\n* Those who agree to give permission to use their human source information\n* Those who agree with this study\n\nExclusion Criteria:\n\n* Those who do not agree with this study\n* Vulnerable participants who are likely to be vulnerable to coercion or undue influence or lack decision-making","20 Years",{"count":224,"type":22},3000,"10 Years","Genitourinary malignancies such as prostate cancer, renal cell cancer, and bladder cancer in Korean population have been increased due to the aged population and the westernized lifestyles. With the advancement of technologies, studies have found that microbiome not only affects human physiological functions, such as metabolism, immunity, and haematopoiesis, but also plays a significant role in the development and progression of malignancies. However, the investigation of microbiome in urological malignances have been limited and few studies have been reported. Therefore, the investigator tried to evaluate the usefulness of microbiome in detection and monitoring of urological malignancies in Korean population. This study aims to use microbiome in tissue, plasma, stool and urine for the diagnosis, disease progression monitoring and therapeutic response evaluation. This study plan includes building big databases for microbiome of urological malignancies in Korean population.",[228,48,229,45,50],"Urological Malignancies","Renal Cell Cancer","2023-01-30",{"date":232,"type":91},"2023-01-31",{"date":234,"type":91},"2022-12-19",{"date":236,"type":22},"2030-10",{"name":238,"class":98},"Yonsei University",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":17,"minAge":222,"maxAge":4,"enrollmentInfo":245,"targetDuration":225,"studyType":24,"phases":4,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":215},"100377660","development-of-urologic-registry-for-personalized-medicine-in-patients-with-urological-malignancy-by-analyzing-circulating-tumor-dna-100377660","NCT04197414","Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA","Inclusion Criteria:\n\n* 1\\. Patients diagnosed as urological malignances (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer)\n* 2\\. Patients who have undergone surgeries due to urological malignancies in Severance Hospital, Sinchon from 2019.12 and 2029.11\n* 3\\. Those who agree to give permission to use their human source information - 4. Those who agree with this study\n\nExclusion Criteria:\n\n* 1\\. Those who do not agree with this study\n* 2\\. Vulnerable participants who are likely to be vulnerable to coercion or undue influence or lack decision-making",{"count":224,"type":22},"Urological malignancies such as prostate cancer and renal cell cancer in Korean population have been increased due to the aged population and the westernized lifestyles. With the advancement of sequencing technologies, use of genetic mutation profiles in cancer detection and progression has been increased. However, use of circulating tumor DNA in urological malignances have been limited and few studies have been reported. Therefore, we tried to evaluate the usefulness of circulating tumor DNA in detection and monitoring of urological malignancies in Korean population. This study aims to use circulating tumor DNA in plasma and urine for the diagnosis, disease progression monitoring and therapeutic response evaluation. This study plan includes building big databases for circulating tumor DNA of urological malignancies in Korean population and to develop optimized circulating tumor DNA platform.",[48,229,45,50],"2019-12-10",{"date":250,"type":91},"2019-12-13",{"date":252,"type":91},"2019-12-06",{"date":254,"type":22},"2029-12",{"name":238,"class":98}]